文献速递衰弱、肌少症与跌倒老年慢病共病管理

衰弱、连续血糖监测指标与胰岛素治疗老年2型糖尿病患者的死亡风险:HARE前瞻性观察队列研究

Characterising frailty, metrics of continuous glucose monitoring, and mortality hazards in older adults with type 2 diabetes on insulin therapy (HARE): a prospective, observational cohort study.
PubMed 文献 · Lancet Healthy Longev · 2021-11-03

HARE为多中心前瞻性观察队列研究,纳入225例70岁及以上、糖尿病病程≥5年、接受胰岛素治疗的社区居住老年人,采用连续血糖监测(CGM)评估衰弱与血糖异常的关系及死亡风险。

要点

  • 衰弱程度加重与CGM中TIR降低及TAR升高相关,而非低血糖。

核心结论

  • 在胰岛素治疗的老年2型糖尿病患者中,衰弱程度加重与血糖异常和高血糖相关,而非低血糖;严重高血糖与死亡风险增加相关。

研究设计与样本

  • HARE为多中心前瞻性观察队列研究,在香港四家医院进行死亡风险分析;纳入225例70岁及以上社区居住、2型糖尿病病程≥5年、接受胰岛素治疗的衰弱老年人。

主要发现

  • 衰弱程度加重与年龄更大、HbA1c更高、肾功能更差及卒中史相关;11项CGM指标中有8项与衰弱显著相关。

关键数值与推荐

  • 血糖控制依据Advanced Technologies and Treatments for Diabetes 2019国际共识临床目标进行表征。

临床怎么用

  • 对胰岛素治疗的衰弱老年2型糖尿病患者,应关注CGM中TIR降低和TAR升高,而非仅关注低血糖。
  • 严重高血糖(level 2 TAR)与死亡风险增加相关,可作为临床管理中的关注指标。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To our knowledge, no previous study has examined the inter-relationship between frailty, dysglycaemia, and mortality in frail older adults with type 2 diabetes who are on insulin therapy. We used continuous glucose monitors (CGMs) to profile this patient population and determine the prognostic value of CGM metrics. We hypothesised that incremental frailty was associated with increased hypoglycaemia or time below range (TBR). METHODS: HARE was a multicentre, prospective, observational cohort study with mortality hazard analysis carried out in four hospitals in Hong Kong. Eligible participants were community-living adults aged 70 years and older; had had type 2 diabetes for 5 years or more; were on insulin therapy; were frail; and were not hospitalised at the time of frailty assessment and CGM recording. Glucose control was characterised according to the Advanced Technologies and Treatments for Diabetes 2019 international consensus clinical targets. Frailty index was computed, and comprehensive frailty assessments and targeted serum metabolic profiling were performed. The Jonckheere-Terpstra test for trend was used to analyse frailty index tertiles and variables. Inter-relationships between CGM metrics and frailty, glycated haemoglobin A1c (HbA1c), and serum albumin were characterised using adjusted regression models. Survival analysis and Cox proportional hazard modelling were performed. FINDINGS: Between July 25, 2018, and Sept 27, 2019, 225 participants were recruited, 222 of whom had CGMs fitted and 215 of whom had analysable CGM data (190 were frail, 25 were not frail). Incremental frailty was associated with older age, greater HbA1c, worse renal function, and history of stroke. Eight of 11 CGM metrics were significantly associated with frailty. Decreased time in range (TIR; glucose concentration 3·9-10·0 mmol/L) and increased time above range (TAR) metrics were strongly correlated with increased frailty and hyperglycaemia, whereas TBR metrics were marginally or not different between frailty levels. Glucose-lowering agents did not significantly affect regression estimates. In patients with HbA1c of 7·5% or more, reduced serum albumin was associated with level 2 TAR (glucose concentration >13·9 mmol/L) and dysglycaemia. During a median follow-up of 28·0 months (IQR 25·3-30·4), increased level 2 TAR was predictive of mortality explainable by frailty in the absence of detectable interaction. Each 1% increment of level 2 TAR was associated with 1·9% increase in mortality hazard. INTERPRETATION: In older adults with type 2 diabetes who are on insulin therapy, incremental frailty was associated with increased dysglycaemia and hyperglycaemia rather than hypoglycaemia. Mortality hazard was increased with severe hyperglycaemia. Future clinical studies and trials targeting actionable CGM metrics highlighted in this study could translate into improved care and outcomes. FUNDING: Health and Medical Research Fund, Food and Health Bureau, The Government of the Hong Kong Special Administrative Region of China.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Fung E, Lui LT, Huang L, et al. Characterising frailty, metrics of continuous glucose monitoring, and mortality hazards in older adults with type 2 diabetes on insulin therapy (HARE): a prospective, observational cohort study. Lancet Healthy Longev. 2021. PMID: 36098029. doi:10.1016/S2666-7568(21)00251-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。